The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has announced its partnership with the Critical Path Institute (C-Path) to explore the feasibility of launching the Lysosomal Diseases Consortium, a public-private partnership among FDA, leading academic institutions, pharmaceutical industries, patient groups, and non-government organizations to address unmet drug development needs for patients living with lysosomal diseases – inherited metabolic diseases that are characterized by an abnormal build-up of various toxic materials in the body’s cells as a result of enzyme deficiencies.
C-Path is an independent, non-profit, public-private partnership that aims to accelerate the pace and reduce the costs of medical product development through the creation of new data standards, measurement standards, and methods standards that aid in the scientific evaluation of the effectiveness and safety of new therapies.
The proposed Lysosomal Diseases Consortium will be under the umbrella of the Accelerating Rare disease Cures (ARC) Program and will focus on generating actionable solutions to accelerate drug development for lysosomal diseases, and to ensure that those solutions reflect current scientific knowledge of lysosomal diseases and regulatory standards for implementation of drug development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze